Release 4

Medicinalproductindication-example.ttl

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: Not linked to any defined compartments

Raw Turtle (+ also see Turtle/RDF Format Specification)

Example of medicinalproductindication

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.org/fhir/MedicinalProductIndication/example> a fhir:MedicinalProductIndication;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "example"];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>diseaseSymptomProcedure</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). <span>(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span></p><p><b>comorbidity</b>: Hipsurgery <span>(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span></p><p><b>intendedEffect</b>: PRYLX <span>(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span></p><p><b>population</b>: </p></div>"
  ];
  fhir:MedicinalProductIndication.diseaseSymptomProcedure [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ema.europa.eu/example/indicationasdisease-symptom-procedure" ];
       fhir:Coding.code [ fhir:value "Venousthromboembolismprophylaxis" ]
     ];
     fhir:CodeableConcept.text [ fhir:value "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)." ]
  ];
  fhir:MedicinalProductIndication.comorbidity [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ema.europa.eu/example/comorbidity" ];
       fhir:Coding.code [ fhir:value "Hipsurgery" ]
     ]
  ];
  fhir:MedicinalProductIndication.intendedEffect [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ema.europa.eu/example/intendedeffect" ];
       fhir:Coding.code [ fhir:value "PRYLX" ]
     ]
  ];
  fhir:MedicinalProductIndication.population [
     fhir:index 0;
     fhir:Population.ageRange [
       fhir:Range.low [
         fhir:Quantity.value [ fhir:value "18"^^xsd:decimal ];
         fhir:Quantity.unit [ fhir:value "a" ]
       ]
     ]
  ] .

# - ontology header ------------------------------------------------------------

<http://hl7.org/fhir/MedicinalProductIndication/example.ttl> a owl:Ontology;
  owl:imports fhir:fhir.ttl;
  owl:versionIRI <http://build.fhir.org/MedicinalProductIndication/example.ttl> .

# -------------------------------------------------------------------------------------


Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.